The ‘don’t eat me’ an­ti­dote: Glax­o­SmithK­line, Roche and No­vo back $86M start­up in high-stakes CD47 show­down

CD47 is a hot prospect in the im­muno-on­col­o­gy world. And Wash­ing­ton Uni­ver­si­ty spin­out Tioma Ther­a­peu­tics plans to be a play­er in that boom­ing R&D game.

It’s an old­er start­up, seed­ed for years to cov­er pre­clin­i­cal work but now prep­ping for a turn in the clin­i­cal spot­light. To­day the com­pa­ny land­ed an $86 mil­lion launch round and an ex­pe­ri­enced biotech hand who is now at the helm. River­Vest Ven­ture Part­ners co-led the round along with a trio of phar­ma heavy­weights: No­vo Ven­tures, Roche Ven­ture Fund and Glax­o­SmithK­line’s S.R. One.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER